Related by context. All words. (Click for frequent words.) 76 log# copies mL 70 #mg BID [003] 69 #.#/#.# mmHg [001] 68 oral allopurinol 68 log# 68 mg QD 68 infliximab monotherapy 68 4mg/kg 68 placebo p = 68 ACR# response 68 receiving INTRON 68 mg TID 68 plus MTX 67 TAXUS p value 67 8mg/kg 67 annualized relapse 67 achieved ACR# 67 log# reduction 67 abacavir lamivudine 67 Peg IFN 67 -#.# log# copies mL 67 -#.# mg dL [002] 67 lopinavir r 67 % Confidence Interval 67 #mg BID [001] 67 plus prednisone prednisolone 67 mcg BID 66 plus prednisone 66 sUA 66 lumbar spine BMD 66 certolizumab 66 QTcF 66 prednisone prednisolone plus 66 budesonide pMDI 66 mg p = 66 clodronate 66 mg qd 66 -#.# mg dL [001] 66 HBeAg seroconversion 66 mmHg p = 66 baseline HbA1c 66 humanized interleukin 6 66 mcg QD 66 mcg kg REBETOL 66 plus methotrexate 66 alfa 2a 66 placebo dexamethasone 66 lopinavir r arm 66 -#.# log# 66 PREZISTA r arm 66 plus dexamethasone 65 mitoxantrone plus 65 Sustained virologic response 65 ritonavir boosted 65 FOLFOX6 65 mg BID 65 complete cytogenetic response 65 anthracycline taxane 65 mcg kg 65 Acetate Rectal Suppositories 65 Hazard Ratio 65 Aptivus ® 65 XIENCE V vs. 65 mL/min/#.# m 2 65 plasma HCV RNA 65 VELCADE melphalan 65 severe neutropenia 64 #mg q8h 64 PEG IFN 64 lispro 64 plus GP IIb 64 #.#mg/dL 64 placebo p 64 oxycodone CR 64 plus OBT 64 statistical significance p 64 interferon alfa 2a 64 mg ustekinumab 64 telaprevir dosed 64 ug kg 64 tolterodine ER 64 Zometa hazard 64 3mg/kg 64 cyclophosphamide methotrexate 64 ACTEMRA TM 64 adjunctive placebo 64 non splenectomized 64 dalteparin 64 pegylated interferon alpha 64 IIIa inhibitor 64 Mg Usa 64 Median PFS 64 peginterferon alfa 2a 64 undetectable virus HCV 64 peginterferon alfa 2b 64 FOLFOX4 alone 64 Pegasys plus Copegus 64 receiving golimumab 64 HBeAg negative patients 64 MCyR 64 mg BID dose 64 pegylated interferon alfa 2a 64 Peginterferon 64 fasting plasma glucose FPG 64 morphometric vertebral fractures 64 dapagliflozin plus 64 plus ribavirin 64 mcg mL 64 achieved undetectable HCV 64 PROCTOCORT ® Suppository Hydrocortisone 64 PASI scores 64 % CI #.#-#.# [003] 64 achieved CCyR 64 mg m² 63 Meets Primary Endpoint 63 x ULN 63 IFN α 63 CIMZIA TM 63 PegIFN 63 #mg QD [002] 63 ribavirin RBV 63 aminotransferase elevations greater 63 μg dose 63 sustained virological response 63 μg kg 63 colesevelam HCl 63 mcg albinterferon alfa 2b 63 undetectable HCV RNA 63 R# #mg BID 63 nadolol 63 mEq L 63 PEGylated anti 63 fluticasone salmeterol 63 mg Lucentis 63 Copegus ribavirin 63 tipranavir r 63 #mg/day [002] 63 comparator arm 63 binary restenosis 63 irbesartan 63 oral antidiabetic medication 63 Pegasys ® 63 rFSH 63 receiving VICTRELIS 63 mg tid 63 BMS p = 63 dexamethasone Decadron 63 q#h 63 dasatinib Sprycel ® 63 stage IIIb IV 63 complete cytogenetic 63 chlorambucil 63 sUA levels 63 dasatinib Sprycel 62 mg RDEA# 62 CIMZIA TM certolizumab pegol 62 saline placebo 62 PegIFN RBV 62 5-FU/LV 62 plus COPEGUS 62 CCyR 62 atorvastatin #mg 62 mg kg dose 62 Q2W 62 Folfox 62 TMC# r 62 adefovir treated 62 naïve HCV 62 Mg Uk 62 sustained virologic response 62 weekly CSBMs 62 ritonavir boosted atazanavir 62 mmol l 62 gemcitabine carboplatin 62 microgram kg 62 ® fluocinonide Cream 62 mg orally 62 rapid virologic response 62 adalimumab Humira 62 nicardipine 62 mg simvastatin 62 gemcitabine cisplatin 62 REMICADE monotherapy 62 COMBIVIR 62 Left Ventricular Ejection Fraction 62 LANTUS R 62 statin monotherapy 62 doxazosin 62 ribavirin therapy 62 oral rivaroxaban 62 FOLFIRI alone 62 piperacillin tazobactam 62 SVR# 62 response CCyR 62 serum urate 62 achieved sustained virologic 62 cytogenetic response 62 alfa 2b 62 tenofovir emtricitabine 62 catheter occlusion 62 hyperphenylalaninemia HPA due 62 mL/min/#.# m2 62 ARB telmisartan 62 atazanavir ritonavir 62 statistically significant p = 62 cells uL 62 mg + GLY 62 μmol L 62 potent CYP#A# inhibitors 62 daily Infergen 62 neutropenia dehydration dyspnea 62 Pharmacokinetics PK 62 FOLFOX4 62 XIENCE V PROMUS Stent 62 telaprevir pegylated interferon 62 myelodysplastic myeloproliferative diseases 62 cisplatin vinorelbine 62 achieved statistical significance 62 corticosteroid dose 62 MACUGEN 62 adjunctive ABILIFY 62 tirofiban 62 Lupuzor ™ 62 TPV r 62 placebo PBO 62 mean baseline A1C 62 % miconazole nitrate 62 cEVR 62 IU mL 62 BARACLUDE ® 62 relapsed MM 62 timolol 62 BUPHENYL R sodium phenylbutyrate 62 FOLFIRI 62 ACE inhibitor ramipril 62 HBeAg positive patients 62 Contrave# 62 mg dosed twice 62 splenectomized 61 Soriatane R acitretin capsules 61 MADRS score 61 REYATAZ r arm 61 CIMZIA ™ 61 dacarbazine 61 PEG Interferon alfa 61 rizatriptan 61 Peginterferon Alfa 2a 61 receiving prophylactic anticoagulation 61 RGT arm 61 CI -#.# 61 beta 1a 61 creatinine ratio 61 methotrexate monotherapy 61 ABC/3TC 61 tapentadol ER 61 peg IFN 61 IOP lowering 61 Lantus ® 61 Cream USP 1 61 Apidra ® 61 IU ml 61 microg 61 biochemical relapse 61 achieved PASI 61 glycated hemoglobin levels 61 ATACAND 61 somatostatin analog 61 ARCOXIA 61 PSA nadir 61 moderate renal impairment 61 Platelet counts 61 undetectable HBV DNA 61 ULORIC 61 mg/m2 IV 61 partial remissions 61 pegaptanib 61 azathioprine monotherapy 61 mcg doses 61 PREZISTA ritonavir 61 plus aztreonam 61 #mg doses [002] 61 pegylated interferon alfa 61 Peginterferon alfa 2b 61 plus glycoprotein IIb 61 #mg QD [001] 61 interferon ribavirin 61 mm Stent 61 candesartan cilexetil 61 Sustained Virologic Response 61 ug dose 61 evaluating tivozanib 61 ® emtricitabine 61 CYP#A# substrate 61 mean baseline HbA1c 61 Engerix B 61 #mg #mg #mg [003] 61 CRESTOR #mg 61 CR nPR 61 active comparator 61 salmeterol fluticasone 61 CR CRu 61 interferon alfa 2b 61 octreotide LAR 61 Hazard Ratio = 61 achieved sustained virological 61 % CI #.#-#.# [001] 61 FluCAM 61 5 Fluorouracil 61 ACR# responses 60 viral kinetics 60 Hycamtin ® 60 diuretic chlorthalidone 60 Flu Cy 60 oral FTY# 60 BENICAR 60 Solid Tumors criteria 60 Soyabean Ext Bulk 60 Pharmacokinetic parameters 60 titrated glipizide plus 60 brand ciclesonide HFA 60 xanthine oxidase inhibitor 60 #/#mg 60 low dose Iluvien 60 oral levofloxacin 60 mg/m2/day 60 pmol L 60 median PFS 60 TAXUS Liberte Long 60 ALT elevation 60 Hb A1C 60 ® lenalidomide 60 noninferior 60 Oral Fingolimod 60 mCi kg 60 REYATAZ r 60 Ishak fibrosis score 60 ug ml 60 ACR# ACR# 60 treatment naive genotype 60 #mg dose [002] 60 doxorubicin cyclophosphamide 60 NovoLog ® Mix 60 low dose cytarabine 60 LPV r 60 COPEGUS 60 RLAI 60 azilsartan medoxomil 60 administered subcutaneously 60 prior chemotherapy regimens 60 TNF Tumor Necrosis Factor 60 Lucentis monotherapy 60 1mg 2mg 60 IV bolus 60 mU liter 60 -#.# ± [002] 60 p = NS 60 urate lowering therapy 60 Tarceva TM 60 XIENCE V demonstrated 60 Aflibercept 60 LEXIVA r 60 Rating Scale MADRS 60 primary hypercholesterolemia 60 Stent p = 60 relapsing multiple sclerosis 60 HOMA IR 60 q8h 60 pyrazinamide 60 confidence interval #.#-#.# 60 creatinine clearance 60 metformin hydrochloride 60 PRADAXA #mg 60 PEGylated Fab fragment 60 μg mL 60 rosuvastatin #mg 60 baseline LDH 60 CRp 60 serum HBV DNA 60 transaminase 60 HbA1c levels 60 Free Survival PFS 60 alanine aminotransferase 60 docetaxel chemotherapy 60 zonisamide SR 60 lamivudine refractory patients 60 β blocker 60 biphasic insulin aspart 60 #.#mmol L [001] 60 interferon alfa 60 tobramycin inhalation solution 60 pegylated interferon peg IFN 60 mcg Albuferon 60 mg kg Hematide 60 mL sec 60 plus medroxyprogesterone acetate 60 refractory NSCLC 60 interferon gamma 1b 60 NPH insulin 60 HAQ DI 60 APTIVUS r 59 ALVESCO 59 peginterferon alfa 2a #KD 59 detectable HCV RNA 59 recurrent NSCLC 59 NNT = 59 Montgomery Asberg Depression 59 #mg/day [001] 59 flutamide 59 hemoglobin A1c HbA1c 59 #/#.# mcg 59 PREZISTA r 59 #mg/kg [002] 59 MAGE A3 ASCI 59 highly emetogenic 59 estramustine 59 generalized edema 59 sumatriptan naproxen sodium 59 #mg/m# [001] 59 liver histology 59 Thal Dex 59 AUA Symptom Score 59 Treatment Naive Patients 59 CTAP# Capsules 59 unfractionated heparin UFH 59 vincristine doxorubicin 59 adriamycin 59 mg subcutaneously 59 alanine aminotransferase ALT 59 nmol liter 59 HBV DNA levels 59 mg kg belimumab 59 mg eq 59 relapsed refractory multiple myeloma 59 infusional 5-FU/LV 59 mcg linaclotide 59 lamivudine monotherapy 59 Doxil ® 59 Castration Resistant Prostate Cancer 59 sham injections 59 Index CDAI score 59 microbiological eradication 59 HbA 1c levels 59 serum phosphorus 59 intravenous REOLYSIN 59 mg/# hours 59 Pegylated Interferon 59 CrCl 59 mg/# mg [001] 59 confirmed CCyR 59 baseline A1C 59 amoxicillin clavulanate 59 Xalatan R 59 baseline serum creatinine 59 mcg kg min 59 mg dose 59 melphalan prednisone 59 Annualized ROE 59 peginterferon alpha 2a 59 serum phosphorous 59 Cutaneous T 59 FUSILEV enhances 59 fumarate 59 #.#/#.# mmHg [002] 59 Cancer AACR NCI 59 insulin detemir 59 Omacetaxine 59 definite stent thrombosis 59 cisplatin gemcitabine 59 hydroxymethyl coenzyme 59 aspartate aminotransferase 59 Pegylated Liposomal Doxorubicin 59 Hazard Ratio HR 59 Crohn Disease Activity 59 benazepril 59 #mg ATC 59 FOLFOX 59 carboplatin paclitaxel 59 -#.# mmol L 59 AZT zidovudine Retrovir 59 cilostazol 59 PEGASYS ® 59 quetiapine XR 59 evaluable subjects 59 apolipoprotein B 59 everolimus eluting stents 59 Lenalidomide 59 neuropathy sensory 59 nadroparin 59 FIRMAGON 59 mg/# mg [002] 59 plus gemcitabine 59 P = .# 59 desvenlafaxine succinate 59 pCR 59 metastatic GIST 59 inhalations twice 59 % #NY.INST 59 pegylated liposomal doxorubicin 59 CLARITY study 59 unresectable tumors 59 febrile neutropenia 59 patients coinfected 59 dose dexamethasone 59 intravenous bolus 59 DAS# remission 59 Operative mortality 59 rimonabant #mg 59 8mg 59 pravastatin therapy 59 biologic DMARD 59 TAXUS Express Stent 59 FSH CTP 59 mg d 59 subcutaneous enoxaparin 59 aspartate aminotransferase AST 59 Response Evaluation Criteria 59 mg q#h 59 DJI #.# 59 RoACTEMRA 59 baseline Hb 59 statistically significant p 59 DOXIL ® 59 taxane chemotherapy 59 - -Books Market Segmentation 59 PEG interferon 59 neutrophil counts 59 TEAEs 58 % CI #.#-#.# [007] 58 Suppository Hydrocortisone Acetate Rectal 58 mmHg diastolic 58 events MACE 58 emtricitabine tenofovir 58 adjuvant GIST 58 elotuzumab 58 progression TTP 58 quetiapine risperidone 58 pooled comparator 58 metastatic CRC 58 docetaxel Taxotere ® 58 treatment naļve 58 HAM D# scores 58 + PH# 58 HCV RESPOND 2 58 Epirubicin 58 titrated glipizide 58 chemoradiation therapy 58 Durezol 58 tipranavir 58 lumbar spine bone 58 mg Proellex 58 Natalizumab 58 detemir 58 BPH Symptom Score 58 % CI #.#-#.# [005] 58 gout flares 58 lymphocytosis 58 glycoprotein IIb IIIa inhibitor 58 adefovir 58 ADCS CGIC 58 baseline neutrophil counts 58 efavirenz EFV 58 mg/m2 dose 58 pg ml 58 autoantibody positive 58 mg q8h 58 FROVA 58 H2RAs 58 insulin glulisine 58 Gary Densham Monte Carlo 58 degarelix 58 AEGR 58 prednisone prednisolone 58 fosamprenavir 58 pg mL 58 virologically suppressed 58 daunorubicin 58 DAPT 58 Elitek 58 goserelin 58 elevated transaminases 58 salmeterol fluticasone propionate 58 randomized #:#:# 58 subcutaneously administered 58 pegylated interferon alfa 2b 58 #R #R #R [002] 58 Fludarabine 58 HbA1c 58 metformin sulfonylurea 58 mso footer margin 58 serum aminotransferase levels 58 Paraplatin ® 58 mild renal insufficiency 58 BENICAR HCT 58 recurrent GBM 58 malignancy HCM 58 bupropion SR 58 microbiologically evaluable 58 docetaxel prednisone 58 q#d 58 mg subcutaneous 58 COZAAR 58 IXEMPRA 58 rufinamide 58 peginterferon alfa 58 uM 58 Viread Emtriva 58 dosing cohorts 58 Biaxin clarithromycin 58 Zevalin R Ibritumomab 58 golimumab CNTO 58 RELEASE ACCORDING TO 58 fluvastatin 58 dose cohort 58 Decitabine 58 mIU ml 58 linaclotide treated 58 primary patency 58 mITT population 58 recurrent glioblastoma multiforme 58 KRAS mutations occur 58 eplerenone 58 mmol L 58 steroid dexamethasone 58 Pred Forte 58 severe renal impairment 58 mg/# h 58 imipenem 58 glimepiride 58 fluoropyrimidine 58 postmenopausal osteoporotic women 58 Mean Symptom Complex 58 nab paclitaxel 58 tacrolimus ointment 58 ng dL 58 confidence interval CI 58 genotypic resistance 58 oxycodone IR 58 rimonabant #mg/day 58 beclomethasone dipropionate 58 conjunctival hyperemia 58 Relapsed Refractory 58 prior relapsers 58 tyrosine kinase inhibitor TKI 58 relapsed CLL 58 ErbB2 positive 58 #mg/dL [002] 58 mEq 58 Virologic 58 pmol liter 58 Greg Stanfield GXP 58 glycosylated hemoglobin HbA1c 58 IIIa inhibitors 58 HBeAg + 58 CANCIDAS 58 PEG Intron 58 mg doses 58 HbA1C levels 58 APTIVUS R 58 anagrelide 58 gemcitabine Gemzar 58 FEET FLOODING 58 bivalirudin monotherapy 58 ARCALYST ® 58 leukopenia 58 antiretroviral naïve 58 pegIFN 58 CLL SLL 58 echinacea tablets 58 febuxostat 58 bendamustine 58 Severity MSCS score 58 A1C levels 58 Score TOS 58 urine albumin 58 #mg dose [003] 58 A1c levels 58 tamsulosin 58 EDEMA3 58 abnormal p# biomarker 58 achieved mucosal healing 58 lymphoid blast 58 Ramipril 58 glulisine 57 azacytidine 57 palifermin 57 BEACOPP 57 CorVue ™ 57 HCV Genotype 57 Sustained Virological Response 57 mm ³ 57 p = 57 mucosal healing 57 SGPT 57 postdose 57 recurrent VTE 57 Partial Response 57 #mg/m# [002] 57 metoprolol tartrate 57 mg Androxal 57 metastatic castration resistant 57 copies mL 57 mg/# hr 57 #.#mg/kg [002] 57 lanthanum carbonate 57 splenectomized patients 57 chronic HCV infection 57 indinavir 57 R entecavir 57 mRCC 57 ropivacaine 57 mIU mL 57 alpha 2a 57 seropositive patients 57 ara C 57 EGYPTIAN POUND 57 baminercept 57 Kivexa 57 BUPHENYL 57 fluorouracil leucovorin 57 aspirin clopidogrel 57 experienced virologic failure 57 Secondary endpoints included 57 HCTZ 57 Primary Endpoint 57 Topotecan 57 #Gy 57 Campath alemtuzumab 57 endoscopic remission 57 angiographic outcomes 57 terfenadine 57 doxorubicin docetaxel 57 null responders 57 HbA1C 57 SGOT 57 g dl 57 bone marrow reticulin deposition 57 deep venous thromboses 57 HCV genotype 57 antiandrogen 57 repeat paracentesis 57 HES CEL 57 adjuvant cisplatin 57 PEGylated interferon beta 1a 57 lumiliximab 57 ORENCIA ® 57 lispro alone 57 lopinavir ritonavir Kaletra 57 TDF FTC 57 RECIST criteria 57 systemic embolism 57 nodular partial response 57 HIV RNA 57 bortezomib refractory 57 aplastic anemia AA 57 Infusion Reactions Severe 57 Scale cognitive subscale 57 forodesine 57 underwent surgical resection 57 MoxDuo TM IR 57 sirolimus stent 57 fatigue asthenia 57 standard chemotherapy regimen 57 PROMACTA 57 serum uric acid sUA 57 Median progression 57 GOUT 57 http:/events.fai.org 57 Index CDAI 57 uncoated stent 57 #.#g/day 57 zoledronate 57 HCV RNA 57 % AST SGOT 57 dosage regimens 57 recurrent genital herpes 57 TNF alpha IL 57 ZOLINZA 57 receiving ISENTRESS 57 #μg [002] 57 aspirin heparin 57 +3 bps 57 Pemetrexed 57 cytidine nucleoside analog 57 HDRS 57 serum phosphate 57 cGy 57 dose melphalan 57 HIV coinfected 57 azathioprine 57 Blended ARPU 57 OGTT 57 investigational oral inhibitor 57 leukemia AML 57 imiquimod cream 57 PegIntron 57 Omacetaxine mepesuccinate 57 #.#/#.# mm Hg [003] 57 teriflunomide 57 urinary N telopeptide 57 MILLION SHARES 57 Posaconazole 57 Nebulized 57 -#.# USD JPY [002] 57 TNF antagonist 57 CIMZIA R 57 TGZ 57 Primary endpoints 57 iniparib 57 Rapid Virologic Response 57 HBeAg 57 nonvertebral fractures 57 undetectable viral 57 epoetin alpha 57 μmol l 57 patients receiving ERBITUX 57 oral antidiabetes 57 neurologic progression 57 valsartan 57 #ug [001] 57 acarbose 57 TRANSFORMS 57 hypophosphatemia 57 placebo Hazard Ratio 57 zolmitriptan 57 oral ridaforolimus 57 activated partial thromboplastin 57 Fludara 57 IRLS score 57 TURBT 57 venlafaxine XR 57 umol L 57 XELOX 57 darunavir r 57 Eur Arch 57 RNA copies mL 57 EGFR TKI 57 SHR VIEW 57 g dL 57 CDAI score 57 DOXIL 57 briakinumab 57 cyclophosphamide FC 57 MLN EUROS 57 mmol kg 57 Tony Pedregon Monte Carlo 57 mycophenolate mofetil 57 nevirapine Viramune 57 #mmHg [001] 57 sitaxsentan 57 alkylating agent 57 inhibitor RG# 57 Zidovudine Tablets 57 5mg/kg 57 IFN alfa 57 #mg ritonavir 57 HBeAg positive 57 tocilizumab 57 g trans fats 56 darbepoetin alfa 56 pimecrolimus cream 56 periprocedural 56 fluticasone propionate 56 Crestor rosuvastatin 56 trimethoprim sulfamethoxazole 56 zidovudine lamivudine 56 cells μL 56 RAPTIVA 56 tamoxifen Nolvadex ® 56 peak plasma concentrations 56 serum urate levels 56 % MID-EAST/AFRICA 56 μg doses 56 prior nephrectomy 56 solifenacin 56 dose cytarabine 56 Besivance TM 56 galiximab 56 clopidogrel Plavix 56 unresectable stage 56 spontaneous bowel movements 56 oral diclofenac 56 headache nasopharyngitis 56 Target Lesion Revascularization TLR 56 severe exacerbations 56 QD dosing 56 aldosterone antagonist 56 subcutaneous insulin 56 dose clopidogrel 56 doripenem 56 FASLODEX 56 Alzheimer Disease Assessment 56 EURIDIS 56 lopinavir 56 RECIST Response Evaluation Criteria 56 Rates Euribor 56 peg interferon 56 FluCAM arm 56 virologic failure 56 ratio ICER 56 non valvular atrial 56 Raptiva r 56 virologic breakthrough 56 #-#,# mg 56 balsalazide 56 interquartile range 56 EDARBI 56 tolvaptan 56 ritonavir boosted lopinavir 56 abciximab 56 cobicistat 56 Psoriasis Area 56 Monotherapy 56 discontinuations due 56 cinacalcet 56 piotr.skolimowski @ thomson.com 56 lactate dehydrogenase LDH 56 pegylated interferon 56 Ranolazine 56 PSADT 56 HCV SPRINT 56 ALIMTA cisplatin 56 fasting plasma glucose 56 NEVO ™ 56 cis retinoic acid 56 mg hydrochlorothiazide 56 nilotinib 56 Forodesine HCl 56 TIMP 1 56 adalimumab 56 p = .# [002] 56 HBV DNA 56 pegylated alpha interferon 56 revascularizations 56 Bezielle 56 dosing cohort 56 LUMIGAN ® 56 angiographic restenosis 56 Eric Medlen Mustang 56 nucleoside naive 56 Emtriva Viread 56 basal bolus therapy 56 idraparinux 56 FOLFOX regimen 56 Gary Scelzi Dodge Stratus 56 CI #.#-#.# [002] 56 treatment naïve genotype 56 arterial thromboembolic events 56 HGS ETR2 56 clinically meaningful improvement 56 ps :# 56 mCi 56 aPTT 56 CI #.#-#.# [001] 56 oral prodrug 56 anthracycline containing 56 oral vancomycin 56 amprenavir 56 dose dabigatran 56 receiving highly emetogenic 56 neutrophil count 56 Gary Scelzi Stratus 56 HBeAg negative 56 ceftazidime 56 PLX STROKE targeting 56 symptomatic VTE 56 3TC lamivudine Epivir 56 REMINYL ® 56 K ras mutations 56 ertapenem 56 reduce serum phosphate 56 micrograms mL 56 sirolimus eluting stent 56 jana.mlcochova @ thomson.com 56 otamixaban 56 AUC0 56 peginterferon 56 ALT flares 56 INCOME TAX EFFECTS 56 antiplatelet medications 56 sorafenib Nexavar 56 oral clodronate 56 HLA DR2 56 J Am Coll 56 virologic response 56 Viread Emtriva Sustiva 56 selective modulator 56 Cmax 56 oral ribavirin 56 LMWH 56 TORISEL 56 deferoxamine 56 tapentadol IR 56 copies ml 56 maximally tolerated dose 56 intravitreal injections 56 abdominal pain abdominal discomfort 56 laboratory abnormalities 56 Tony Pedregon Impala 56 ug mL